Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia
Journal of the ASEAN Federation of Endocrine Societies
- Dapagliflozin
- Semaglutide
- GLP-1 and incretin signalling
- Lipid and ceramide metabolism
- Type 2 diabetes
- Humans
The paper
Rasmah Alharajin, Muneera AlTaweel, Maram AlSubaiee, Mareyah Alshaikh Husain
Show 20 more authors
Saleh Almekhloof, Abdulmohsen Almusaad, Abdulrahman Abdullatif Alarfaj, Ahmad Khalid Alkhayyal, Noor M Altharman, Ahmed Alalawi, Noora Almannai, Munirah Alohaymid, Afnan Alsaad, Turkiah Alotaibi, Reem Alkhaldi, Ghusoon Almoaibed, Jawaher AlRashada, Abdullatif Waleed Alarfaj, Turki Alqarni, Abdullah Alshahrani, Ibrahim Fahad Aldossary, Seham Khashwayn, Ali AlQarni, Yaqob Taleb,King Saud bin Abdulaziz University for Health Sciences · King Abdulaziz Hospital
Journal of the ASEAN Federation of Endocrine Societies · 13 Aug 2026 · CC BY-NC